SELLAS Life Sciences Group, Inc. Common Stock SLS

$11.88 -4.27% at last close
Market Cap$2.51 billion
P/E Ratio—
Div Yield8.09%
Volume4.74M
52-Week Range $1.39$15.88

Analyst Ratings

Consensus
Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
Avg. Price Target
$10.00 (-15.8% downside)

Full SLS forecast & analyst actions →

Key Stats

Today's Range
$11.71 – $12.44
50-Day Range
$10.71 – $15.67
52-Week Range
$1.39 – $15.88
Volume
4.74 million shs
Average Volume
5.78 million shs
Market Cap
$2.51 billion
P/E Ratio
—
Dividend Yield
8.09%

Dividend

Dividend Yield
8.09%
Annual Dividend
$0.96
Payout Ratio
—
Ex-Dividend Date
2011-03-24

Short Interest

Short Interest
0.06%
Days to Cover
2.01

About SELLAS Life Sciences Group, Inc. Common Stock

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
13
Exchange
XNAS
Listed
2008-03-12

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.